Our expert oncology teams meet periodically to discuss important developments in cancer management and explore innovative ways to advance clinical practice.
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer
This expert team explores important oncology developments related to breast cancer management, with a emphasis on new findings and areas where guidance from established bodies, such as the National Comprehensive Cancer Network (NCCN) and the American Society for Clinical Oncology (ASCO), may be unresolved.
The GICTEG is a group of expert oncology physicians and clinical researchers who have dedicated their careers to the treatment of patients with gastrointestinal cancer, with a particular emphasis on new findings in oncologist education. The goal is to elicit the group’s opinions on a given topic as it relates to their own clinical practices, and more importantly, how this might impact busy oncologists in the community setting, where gastrointestinal cancer is only one of many tumor types encountered.